Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for ...

Solid Biosciences Inc.’s SLDB share price has dipped by 14.97%, which has investors questioning if this is right time to buy.

Biogen enhances its portfolio and margins amidst market challenges and competition. Click here to find out why BIIB stock is ...

Larimar Therapeutics, Inc. (Nasdaq: LRMR) has announced significant progress in its nomlabofusp program for Friedreich’s ...

Anthony Monaco was a very active teen—involved in soccer, wrestling, and even cross country—but he always felt a little awkward physically. It started with running a little differently than the kids ...

After getting a green light from the European Commission, Biogen’s Skyclarys is the first approved medicine for the inherited neurological disease Friedreich’s ataxia (FA) in the EU.

Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver ...

Learn more about whether Alvotech or PTC Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which ...

Equities researchers at HC Wainwright dropped their FY2025 earnings per share estimates for Larimar Therapeutics in a ...

Investment analysts at Leerink Partnrs dropped their FY2025 earnings estimates for shares of Lexeo Therapeutics in a report ...

Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver de-targeting, in NHP study - - Preclinical muri ...